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 The human papillomavirus (HPV) is the cause of nearly all cases of cervical 
cancers worldwide. HPV viral DNA is found in more than 99% of cervical cancers. In 
addition to cervical cancer, HPV is also associated with some breast and oral cancers. 
White women have been showing a decline in breast cancer rates while black women are 
continuously showing higher rates of mortality from both breast and cervical cancer. 
Minority women are also more likely to receive a late diagnosis and are showing 
increased incidence of oral cancer, which makes study of HPV in women and minorities 
significant. 
To date, little evidence has been provided to estimate oral HPV prevalence among 
healthy adults in the US. A few select international studies have evaluated HPV 
prevalence in healthy adults using biopsy samples and these results show HPV 
prevalence ranging from 0 – 15%.   More recently, new international studies have begun 
to report less invasive saliva-based testing methods to successfully screen for oral HPV 
infection among healthy adults, revealing prevalence rates of approximately 20%.  To 
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date, there are no reports of saliva-based HPV screening studies of normal, healthy 
adults, rather than oral cancer patients, to screen for oral prevalence in the U.S.  
The goal of this study was to collect saliva from the University of Nevada Las 
Vegas – School of Dental Medicine (UNLV-SDM) patient clinic and screen for the 
presence of the high risk strain, HPV 16, found in the majority of HPV-associated 
cervical, breast, and oral cancers. Two hundred participants were asked to provide a 
saliva sample for HPV screening. Demographic information such as age, gender, and race 
were also obtained for statistical analysis. DNA was isolated from the saliva sample in 
order to perform PCR to screen for HPV 16.  
Analysis of the UNLV-SDM patient population revealed a higher percentage of 
females and minorities than in the local community, Clark County.  Analysis of the 
demographic information from the saliva samples revealed that these samples were 
representative of the UNLV-SDM patient pool.  Four (4) samples tested positive for 
HPV16 (all from women and minority participants) from more than one hundred samples 
screened (n=102). Although the prevalence of HPV16 in this study was relatively low 
(3.9%), it is comparable to other studies of oral HPV (range 0 -21%).This study is 
significant because it is the first saliva-based oral HPV screening on healthy adults to be 
completed in the U.S. and only the third study of its kind overall.   
Future studies might incorporate larger sample sizes and provide alternative sites 
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Purpose of the Study & Specific Aim  
The overall purpose of this research project was to screen University of Nevada 
Las Vegas-School of Dental Medicine (UNLV-SDM) patients for oral HPV. UNLV-
SDM, with more than 90,000 active patients, is uniquely positioned to perform oral 
screening and oral HPV testing among this patient population.  A UNLV Office of 
Research Integrity – Human Subjects protocol (#1002-3361- The Prevalence of Oral 
Human Papilloma Virus in the UNLV School of Dental Medicine Clinic Population) has 
been approved to sample and study HPV infection among these patients.   




HPV is a non-enveloped DNA virus. There are greater than 100 types of HPV 
which are classified into low and high risk types. Low risk types of HPV are more 
commonly associated with warts while high risk types of HPV are associated with 
cancers. HPV is associated with many cancers, but for the purpose of this study, cervical, 
breast, and oral cancers will be discussed. This study specifically focuses on HPV 16, a 
high-risk strain, due to its presence in cervical, breast, and oral cancers. Even though 
almost everyone gets infected with HPV, the immune system can rid itself of 
papillomaviruses, but persistent viruses can develop into warts and even lead to cancer 
(Kersiek , 2008). HPV 16 is the most prevalent strain in oral and breast cancers (Kingsley 






Cervical cancer is a disease that is both preventable and curable. The 
papanicolaou cytological test (Pap smear) is a screening tool used to detect abnormalities 
in the cervix of women. If cervical cancer is detected early it can be cured. Screening is 
imperative for all women, despite socioeconomic status. “Cervical cancer is a disease 
most frequently found in poverty-stricken communities and reflecting a problem of 
equity at both levels: gender and regional, and this is not only due to social and economic 
development inequalities, but also due to the infrastructure and human resources 
necessary for primary care” (Chankapa et al., 2011).  
HPV is the cause for cervical cancer and has been linked to more than 99% of 
cervical cancers (Andrews et al., 2008). According to the Centers for Disease Control and 
Prevention (CDC), cervical cancer is the most common cancer associated with HPV 
(CDC, 2009). Cervical cancer is the second most common cancer in women worldwide 
(Verhoeven et al, 2009; Confertini et al., 2010). In the U.S., Black and Hispanic women 
are at a higher risk for cervical cancer (Downs, 2010). Moreover, Black women may not 
receive the best care available and therefore are more likely to die from cervical cancer 
(Coker et al., 2009). According to a meta-analysis based on over fifty studies, individuals 
with low socioeconomic status (SES) compared to individuals with a high SES had a 
two-fold increased risk for cervical cancer (Benard et al., 2008). Risk factors for cervical 
cancer include: age of first sexual contact, number of sexual partners, history of sexually 
transmitted disease, diet, and environment. Gillison and Shah (2003) suggested that the 
sexual practices of women, sexual practices of their male partners, and the standard of 
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health care, in regards to an effective screening program, are the major factors related to 
cervical cancer. 
Breast Cancer 
While breast cancer is the second most common cancer in the world, affecting one 
in eight women, it is the leading type of cancer affecting women worldwide (Shukla, 
2009). HPV is relevant in breast cancer since high risk types of HPV have been seen in 
approximately 50% of breast cancer biopsies (Kingsley et al., 2009). Mammography is 
the most effective method for detecting cancer of the breast(s). Often times minority 
women do not get screened or are infrequently screened which can lead to a late 
diagnosis and mortality risk. Even though mortality rates for breast cancer have been 
steadily declining, rates for American Indian and Alaska Natives have been increasing 
(Engelman et al., 2011). Possible barriers that may prevent screening are fear of pain, 
beliefs, embarrassment, lack of insurance, and the ability to pay. 
Oral HPV 
 
Twenty five percent of oral cancers may be linked to HPV (CDC, 2009) with 
HPV 16 being the most predominant type detected in oral cancers. Risk factors for oral 
cancer may include: alcohol consumption, tobacco use, HPV, oral hygiene, diet, family 
history, age, gender, and race. The main risk factors are alcohol and tobacco use, which is 
a concern for minorities since minorities are more likely to use alcohol and tobacco 
products. Cigarette smoking was first identified in 1957 as an independent risk factor for 
oral and oropharyngeal cancer (Ragin et al., 2007). In essence, tobacco products were 
confirmed, along with alcohol, as the two major risk factors for developing oral and 
oropharyngeal cancers (Ragin et al., 2007). Furthermore, diets that do not meet the 
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appropriate levels for fruit and vegetable consumption are also related to the risk of 
developing oral cancer. Oral cancer is a major concern because the number of women 
with oral and pharyngeal cancers is expected to increase well beyond cervical cancer 
(Lyda, 2010). 
Experimental Design 
This study involves a prospective, cluster study design. This proposal involves 
using a cluster sample, located at the UNLV School of Dental Medicine.  The 
investigators selected patients for participation based upon the following criteria. The 
inclusion criteria required participants to: be a current patient at UNLV-SDM; be over 
eighteen years of age; agree to participate; and provide Informed Consent. The exclusion 
criteria excluded participants under the age of 18 and those who did not wish to 
participate. 
Research Questions and Hypotheses 
 
1. How does the UNLV-SDM patient population demographics (gender, race, age) 
compare to the population of Southern Nevada (Clark County)?   
Null hypothesis: There is no difference between UNLV-SDM and Clark County 
population demographics 
Alternative hypothesis: There is a difference between UNLV-SDM and Clark 
County 
 
2.  How does the HPV screening sample demographics (gender, race, age) compare with 
the UNLV-SDM patient population? 
Null hypothesis: There is no difference between HPV sample and UNLV-SDM 
population 
Alternative hypothesis: There is a difference between HPV sample and UNLV-
SDM 
 
3.  What is the prevalence of high-risk HPV in the sample population? 
No hypothesis: There is no current information for comparison 
 
4.  How does this study compare with published oral HPV prevalence? 
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Null hypothesis:  There is no difference between UNLV sample and other oral 
HPV studies 
Alternative hypothesis:  There may be a difference between UNLV sample and 
other oral HPV studies; although it is not known whether this will be higher or 
lower. 
Predictions  
It is predicted that there is a difference between UNLV-SDM demographics and 
Clark County; There is no difference between HPV sample and UNLV-SDM population; 
Since no current information is available, no comparison can be made on the prevalence 
of high risk HPV in the sample population; and there is a difference between UNLV 
sample prevalence and other oral HPV publications. 
Preliminary Results 
To answer the first research question, comparing the UNLV-SDM patient 
population demographics (gender, race, age) to the population of Southern Nevada (Clark 
County), US Census data were analyzed to determine the percentage of females, 
minorities and those within specific age ranges.  These results demonstrate that the 
UNLV-SDM population was similar to Clark County with respect to gender, with 
approximately equal percentages of females and males (Table 1.1).  More specifically, 
the percentage of females at UNLV-SDM was 50.6%, which is statistically higher than 
the percentage in Clark County 49.1%, although this makes little practical significance. 
The percentage of minorities, Blacks and Hispanics, were greater at UNLV-SDM (15.3% 
and 41.4%) than in Clark County (10.6% and 29.3%).  UNLV-SDM also had higher 
percentages of patients 18-64 and 65+ (70.5% and 12.2%) compared with Clark County 
(63% and 10.7%).  These data demonstrate that UNLV-SDM has a significantly different 
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composition of patients than the surrounding community, therefore the alternative 
hypothesis can be accepted. 
Table 1.1 Demographic analysis of Clark County and UNLV-SDM 
________________________________________________________________________ 
Variables Clark County  Expected  Observed 
         UNLV-SDM  p-value 
________________________________________________________________________ 
Gender 
Female  N = 934,291 (49.1%)  (.491) 71,051  50.6% 
       n = 34,886  n = 35,952     
                   X2 = 61.3 
                    df = 1   
                    p < 0.001 
Male  N = 966,640 (50.8%)  (.508) 71,051  49.4% 
       n = 36,093  n = 35,099     
                    X2 = 61.3 
                    df = 1   
                    p < 0.001 
------------------------------------------------------------------------------------------------------------ 
Race 
White  N = 953,320 (50.1%)  (.501) 71,051  40.8% 
       n = 35,597  n = 28,989     
                X2 = 2458.3 
                df = 1   
                 p < 0.001 
Black  N = 201,700 (10.6%)  (.106) 71,051  15.3% 
       n = 7,531  n = 10,871     
                X2 = 2458.3 
                 df = 1   
                 p < 0.001 
Hispanic N = 557,530 (29.3%)  (.293) 71,051   41.4% 
       n = 20,818  n = 29,415    
                X2 = 2458.3 
                df = 1   
                 p < 0.001 
------------------------------------------------------------------------------------------------------------ 
Age 
18 - 64 years N = 1,198,785 (63%)  (.63) 71,051  70.5% 
       n = 44,762  n = 60,598     
                X2 = 6671.1 
                df = 1   
                 p < 0.001 
65+  N = 190,283(10.7%)  (.107) 71,051  12.2% 
       n = 7,602  n = 10,453     
                X2 = 6671.1 
                df = 1   




 The remaining three research questions were answered in a publication in the 











HPV SCREENING & DETECTION 
This chapter has been submitted (and accepted) for publication to the peer-
reviewed scientific journal BMC Oral Health and is presented in the style of that journal. 
High-risk human papillomavirus (HPV) screening and detection in normal, healthy 
patient saliva samples: a pilot cluster randomized study. 
Deidre O Turner1, Shelley J Williams2, Ryan Bullen3, Jeremy Catmull3, Jesse Falk3, 
Daniel Martin3, Jarom Mauer3, Annabel E Barber2, Shawn L Gerstenberger1, Karl 
Kingsley3*. 
1 University of Nevada, Las Vegas – School of Community Health Sciences, Department 
of Environmental and Occupational Health, Las Vegas, Nevada, USA  
2 University of Nevada, Reno – School of Medicine, Department of Surgery, Las Vegas, 
Nevada, USA 
3 University of Nevada, Las Vegas – School of Dental Medicine, Department of 
Biomedical Sciences, Las Vegas, Nevada, USA 
Abstract 
Background: The human papillomaviruses (HPV) are a large family of non-
enveloped DNA viruses, mainly associated with cervical cancers.  Recent epidemiologic 
evidence has suggested that HPV is an independent risk factor for oral cancers, 
suggesting HPV may modulate the malignancy process in some tobacco- and alcohol-
induced oral cancers, but may also be the primary oncogenic factor for inducing 
carcinogenesis among non-smokers. Little evidence, however, is available regarding oral 
HPV prevalence among healthy adults in the US.  The goal of this study was to perform a 
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non-invasive, saliva-based HPV screening of normal healthy adults to assess oral HPV 
prevalence.   
Methods 
Healthy, adult patients at a US dental school were randomly selected to 
participate in a clustered pilot study. DNA was isolated from saliva samples and screened 
for HPV16 using PCR. A small subset were subsequently screened using qPCR to 
confirm analytical sensitivity and specificity. 
Results: Chi-square analysis revealed the random patient sample was 
representative of the general clinic population with respect to gender, race and age (p > 
0.05).  Four patient samples were found to harbor HPV16 DNA, representing 3.9% of the 
total (n = 102).   Three of the four HPV16-positive samples were from patients under 65  
years of age and all four were female and Hispanic. 
 Conclusions: The successful recruitment and screening of healthy, adult patients 
revealed HPV16 was present in a small subset of minority females.  These results provide 
new information about oral HPV status, which may help to contextualize results from 
other studies that demonstrate oral cancer rates are increasing in the US among both 
females and minorities and in some geographic areas – and may be associated with risk 
factors other than tobacco and alcohol use.  Although future studies may explore the role 
of other factors that influence oral HPV exposure, as well as the short- and long-term 
consequences of oral HPV infection, the results of this study may be of significant value 






The human papillomavirus (HPV) has been implicated as the cause of virtually all 
cervical cancers worldwide [1-3].  These represent a large family of non-enveloped DNA 
viruses that may be found integrated into the host genome, non-integrated or episomal, or 
as a combination or mixture of these types in infected tissues [4-9].  HPV viruses infect 
many types of epithelial cells, with intraepithelial neoplasias accounting for the 
overwhelming majority of HPV-related cancers [10,11]. 
More than one hundred types of HPV have been identified and classified.  These 
HPV types may be the primary oncogenic or etiologic cause of cancer or are associated 
with other dermatologic disorders, including the development of warts [12,13]. The HPV 
strains determined to be oncogenic have been classified as high-risk, with HPV16 and 
HPV18 the most prevalent - accounting for the overwhelming majority of all HPV-
associated cancers [14].  Other HPV strains, more commonly associated with genital and 
anal warts, or other skin and epithelial disorders, have been classified as low risk.  These 
include HPV types 6 and 11, among many others [15].  Although the majority of these 
HPV strains were originally identified in cervical lesions, more recent evidence has 
demonstrated their presence in other tissues including colorectal, penile, breast, lung, and 
oral tissues [16-27].  
Recent epidemiologic evidence has suggested that HPV is an independent risk 
factor for oral cancer, revealing HPV in three times as many pre-cancerous oral lesions, 
and almost five times as many oral cancers, compared with normal oral mucosa [28-30].  
Although the traditional risk factors for developing oral cancer remain tobacco use and 
heavy alcohol consumption, these data suggest other risk factors, such as HPV, may play 
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significant roles in determining whether oral cancer develops and how quickly it may 
progress [31-34].  Of all HPV types, the high-risk strains HPV16 and HPV18 are the 
most commonly identified from biopsies of oral cancers [19-21], providing strong 
evidence that HPV may be an independent risk factor for oral cancer. 
The role of HPV in the oral cavity, however, may differ by anatomic site and also 
by the particular strain of HPV infection [35].  For example, low-risk HPV strains 6 and 
11 have been identified in benign laryngeal papillomas, common warts (verruca 
vulgaris), and condyloma acuminatum [36-38].  These strains have also been found in 
uncommon cancers, such as Ackerman’s (verrucous carcinomas) [39] and Buschke-
Lowenstein tumors [40]. Conversely, high-risk strains HPV-16, and to a lesser extent 
HPV-18, are found in nearly half of all oral squamous cell carcinomas and epithelial 
lesions [33,41,42].   
The comparatively low presence of high-risk HPV in normal tissues and much 
higher prevalence in oral cancers may suggest that HPV preferentially infects already 
developing oral cancers [28-30].  HPV may then subsequently function to modulate the 
malignancy process in developing or establish oral cancers, as has been observed in 
studies of HPV infection in other developing cancers [23,43-45]. Recent epidemiologic 
and case-control studies have demonstrated that patients with HPV-positive tumors had 
significantly better response rates to chemotherapy and chemoradiation treatments when 
compared with HPV-negative tumors [28,46-48].  Several in vitro studies have 
investigated possible mechanisms that may account for these phenotypic changes in oral 
cancers [49,50].  Evidence that HPV infection in oral cancers correlates with increased 
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survival rates and better prognosis among some patients is now accumulating, possibly 
due to changes in cellular responsiveness [45,51,52]. 
Despite these findings, rates of oral cancer in the United States (US) have been 
rising among some subgroups within the population, and in specific geographic areas 
[34,53-56].  The steady decrease in the number of current smokers in recent years, 
combined with an ever-increasing percentage of never smokers in the US [33], suggests 
that other risk factors are likely responsible, in part, for these observed increases.  One 
recent study found that although a majority of oral cancers in the US were linked with 
tobacco and alcohol consumption, a significant minority were not [57].  More 
importantly, this study found non-tobacco and non-alcohol related cases were six times 
more likely to harbor HPV infections than controls.  Based upon this information, it is 
likely that HPV may modulate the malignancy process in some tobacco- and alcohol-
induced oral cancers, thereby altering their phenotypes, but may also be the primary 
oncogenic factor for inducing carcinogenesis among non-smokers. 
To date, little evidence has been provided to estimate oral HPV prevalence among 
healthy adults in the US.  A few select international studies have evaluated HPV 
prevalence in healthy adults using biopsy samples, revealing prevalence rates that ranged 
from 0 – 15% [41,58-62].   More recently, new international studies have begun to report 
less invasive saliva-based testing methods to successfully screen for oral HPV infection 
among healthy adults, revealing prevalence rates of approximately 20% [63-65].  To date, 
there are few reports of saliva-based HPV screening studies of normal, healthy adults, 
rather than oral cancer patients, to screen for oral prevalence in the US.  Based upon this 
information, the goal of this project was to perform a non-invasive, saliva-based HPV 
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screening of normal healthy adults.  This screening was performed in Nevada, a state 
recently documented to have increasing rates of oral cancer – despite declining rates of 
oral cancer nationally and declining rates of tobacco and alcohol use in the state [34,56].  
Methods 
Human Subjects  
The protocol for this study titled “The Prevalence of Oral Human Papilloma Virus 
(HPV) in the University of Nevada, Las Vegas - School of Dental Medicine (UNLV-
SDM) Clinic Population” was filed, amended, and approved by the UNLV Office of 
Research Integrity – Human Subjects (OPRS#1002-3361) on April 9, 2010.  In brief, 
subjects were recruited by members of the UNLV-SDM Clinic during their dental visit 
on one of fifteen (15) clinic dates. Informed Consent was required and was conducted 
onsite. Inclusion criteria: subjects had to be eighteen (18) years old or older and must 
agree to participate.  Exclusion criteria: subjects younger than eighteen (18) years of age 
and subjects with prior diagnosis of oral cancer were excluded from participation.  
Saliva Collection Protocol  
In brief, healthy adults who agreed to participate were given a small saliva 
collection container, 50 mL sterile polypropylene tube, Fisher Scientific (Fair Lawn, NJ).  
Participants were then asked to chew on a small piece of paraffin wax for one (1) minute 
and then to expectorate.  Each saliva sample was assigned a unique, randomly-generated 
number to prevent research bias.  Demographic information regarding the sample was 
concurrently collected, which consisted of age, gender, and ethnicity only.  Samples were 




DNA isolation and polymerase chain reaction (PCR) 
To determine if any samples harbored the HPV virus, DNA was isolated from the 
saliva using the GenomicPrep DNA isolation kit (Amersham Biosciences: 
Buckinghamshire, UK), using the procedure recommended by the manufacturer.  DNA 
from each sample was then used to perform PCR with the Fisher exACTGene complete 
PCR kit (Fisher Scientific: Fair Lawn, NJ) and a Mastercycler gradient thermocycler 
(Eppendorf: Hamburg, Germany) using the following primers for HPV16 and 
glyceraldehyde- 3- phosphate dehydrogenase (GAPDH), synthesized by SeqWright 
(Houston, TX):  
HPV16 forward primer, ATGTTTCAGGACCCACAGGA;   
HPV16 reverse primer, CCTCACGTCGCAGTAACTGT.  
GAPDH forward primer, ATCTTCCAGGAGCGAGATCC;   
GAPDH reverse primer, ACCACTGACACGTTGGCAGT;  
One μg of template DNA was used for each reaction.  The initial denaturation 
step ran for three minutes at 94°C.  Thirty amplification cycles were run, consisting of 30 
second denaturation at 94°C, 60 seconds of annealing at 58°C, and 30 seconds of 
extension at 72°C.  Final extension was run for five minutes at 72°C.  The PCR reaction 
products were separated by gel electrophoresis using Reliant 4% NuSieve® 3:1 Plus 
Agarose gels (Lonza: Rockland, ME).  Bands were visualized by UV illumination of 
ethidium-bromide-stained gels and captured using a Kodak Gel Logic 100 Imaging 





Quantitative PCR assay 
HPV16 primers were designed to amplify genomic DNA isolated from the saliva 
samples. The first pair targeted HPV16 in the E6 region, with the second pair targeting 
beta actin (β-actin). Real-time PCR conditions were conducted using the procedure 
recommended by the manufacturer. The DNA quantity based on HPV16 gene data was 
normalized using the DNA quantity of β-actin as a reference.  
Statistical evaluation 
Following the acquisition of saliva samples and HPV screening results, 
demographic information from each sample was compared with the overall demographic 
profile of the UNLV-SDM patient pool (N = 71, 051) using a chi-square (χ2) test, to 
determine if any characteristic (gender, race, age) was different than expected among the 
patients evaluated in this study (n = 102).  A probability level of alpha (α) = 0.05 was 
used to determine significance.  Sensitivity and specificity were calculated as the 
proportion of true positives and true negatives (cutoff value >0.1 copies/genome), 
respectively. 
Results 
One hundred and fifty one (151) samples of saliva were collected from the 
UNLV-SDM patient clinic between June 2 and October 1, 2010.  The patients from 
whom the randomly collected saliva samples were obtained were similar to the overall 
UNLV-SDM clinic population with respect to gender (Table 1).  More specifically, the 
total number of females and males was roughly equal (52.3% and 47.7%, respectively) 
and not significantly different (p > 0.05).  However, there were slightly more White 
patients in the study population (48.3%) than in the overall UNLV-SDM population 
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(40.8%), which approached statistical significance (p < 0.1, p > 0.05).  In addition, there 
were also slightly fewer 18 – 64 year olds in the study population (80.8%) than in the 
overall clinic (85.3%), which also approached statistical significance (p < 0.1, p > 0.05).   
DNA was successfully isolated from one hundred and two (102) of the collected 
saliva samples, which were subsequently screened for the presence of HPV-16 (Table 2). 
Of the total number tested, only four (4) patient samples were determined to be HPV-16 
positive, which represented 3.9% of the total screened.  All four samples were taken from 
females (p< 0.01) who were non-White (p<0.05), a result significantly different than 
expected.  Three of the four samples were from patients between 18 – 64 years of age, 
and one sample came from a patient over 65 years of age.  
Ten HPV-negative samples were selected at random to be screened in duplicate, 
using quantitative PCR (qPCR) to provide quantitative assessment, as well as the four 
HPV-positive samples (Table 3).  These data confirm the four HPV-positive samples 
were true positives, yielding normalized copy numbers significantly higher than 
previously established cutoff values (>0.1 copies/genome).  In addition, all ten HPV-
negative samples were confirmed to have detectable levels below this cutoff value (range: 
0.0003 – 0.0000016 copies/genome).  Using more stringent (>0.001 copies/genome) and 
less stringent (>0.1 copies/genome) cutoff values did not alter these results, providing 
evidence that no false positives or false negatives were among the qPCR-screened 
samples.  The proportion of true positives (4/4 or 100%) and true negatives (10/10 or 




Graphic analysis of qPCR results revealed striking differences in HPV-16 copy 
numbers between HPV-negative and HPV-positive samples (Figure 1).  Analysis of the 
range of copy number/genome for the housekeeping gene (β-actin) within HPV16-
negative (range: 4 – 363 copies/genome) and HPV-positive samples (range: 75-1096) 
were similar and well above the cutoff value (>0.1 copies/genome).  However, analysis of 
the range of copy number/genome for HPV-16 demonstrated clearly divergent values 
among the HPV16-negative (range: 0.0003 – 0.0000016 copies/genome) and HPV-
positive (range: 70 – 111 copies/genome) samples, which were easily distinguished using 
the cutoff value (>0.1 copies/genome).    
Discussion 
The primary aim of this study was to perform a non-invasive, saliva-based HPV 
screening of normal healthy adults within the patient population at UNLV-SDM.  More 
than one hundred samples were successfully collected and screened for HPV, revealing a 
prevalence rate in this population of 3.9% (n = 102).  Secondary analysis and screening 
of these samples using qPCR demonstrated no false positives or false negatives, 
providing further quantitative evidence of sufficient sensitivity and specificity within 
these results. 
These data suggest a prevalence rate that is slightly higher than the most recent 
evidence, which demonstrated oral HPV prevalence in a multinational study of healthy, 
cancer-free patients of approximately 1.3% (n = 1680) [66,67].  Over the past few 
decades, a few select international studies have also evaluated HPV prevalence in healthy 
adults using  biopsy samples, which reported widely variable prevalence rates that ranged 
from 0 – 15% [41,58-62].   The few published reports to screen for oral HPV infection 
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among healthy adults using saliva-based testing methods, however, reported much higher 
prevalence rates of approximately 20% [63-65].  The results of this current study provide 
new data from a previously unscreened patient population (and geographic area) to 
complement the growing corpus of information about oral HPV prevalence among 
healthy adults.   
This study also provides critically important information because it is among the 
first to evaluate the prevalence of oral HPV infection among a patient population in 
Nevada, one of the only US states to have increasing short-term oral cancer incidence and 
mortality rates [56].  Although an analysis of the primary risk factors for oral cancer 
revealed higher rates of tobacco use and smoking prevalence in Nevada than in 
neighboring states, these rates were found to be steadily decreasing over time [34] – 
suggesting other confounding variables or risk factors may also be important.  Based 
upon this evidence, evaluation of other independent risk factors for developing oral 
cancer, including infection with high risk HPV, becomes crucial. 
In addition, the results of this study found oral HPV infection only among patients 
who were also minority and female.  Although the vast majority of female and minority 
patients in this study were found to have no evidence of oral HPV infection, recent 
epidemiologic studies have shown that rates of oral cancer haven risen sharply among 
females in the US despite declining rates among males [54].  Moreover, rates of oral 
cancer have also been rising among minority populations in the US [53], despite an 
overall decline among the general population, and the non-minority population, more 
specifically [34,56].  Although the sample size in this study is limited, the results suggest 
that further investigation may be warranted. 
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This study had several limitations to be considered.  Although the study was able 
to recruit and screen a significant number of patients, due to the preliminary nature of this 
pilot study, the overall sample size was somewhat limited.  Future studies that are able to 
allocate more significant time and resources, could significantly increase the overall 
sample size evaluated. In addition, detailed demographic and behavioral data were not 
designated as critical to the initial goals of this pilot study, however, the inclusion of 
smoking and tobacco use, as well as more detailed information about other behaviors, 
housing, education, income, and other socioeconomic indicators may provide additional 
insights for future investigations.  Finally, screening for other high-risk HPV strains, 
including HPV18 or other oral infectious agents, may be possible in future studies with  
more significant resources and personnel.  
Conclusions 
The goal of this study was to evaluate prevalence of HPV16 from a patient sample 
in a pilot study at the UNLV-SDM.   This study successfully recruited patients and 
screened samples that confirmed HPV16 was present in a small subset of the healthy, 
adult patients.  Moreover, the patients with oral HPV16 infection were both female and 
minority.  Although oral cancer has traditionally been associated with White males, 
recent studies have found that rates of oral cancer are increasing in the US among both 
females and minorities – and may be associated with risk factors other than tobacco and 
alcohol use.  Although future studies may explore the role of other factors that influence 
oral HPV infections, as well as the short- and long-term consequences of oral HPV, the 
results of this study may be of significant value as other dental, medical, health care, and 
professional schools evaluate and integrate this evidence to further our understanding of  
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oral health and disease risk.  
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Figure 1. Graphic analysis of qPCR HPV screening results.  Plotting of copy 
number/genome for housekeeping gene (β-actin) was similar from samples of HPV-
positive (range: 75-1096) and HPV-negative samples (range: 4 – 363 copies/genome).  
Copy number/genome using qPCR was significantly above the cutoff value (>0.1 
copies/genome), confirming the HPV-positive samples did harbor HPV DNA (range: 70  
– 111 copies/genome).  Values for HPV-negative samples were well beneath the cutoff 

































Table 1. Demographic analysis of study participants 
________________________________________________________________________ 
Variables  UNLV-SDM   Study sample  p-value 
________________________________________________________________________ 
Gender 
Female  n = 35,952  (50.6%)  n = 79 (52.3%) p > 0.5 
Male   n = 35,099 (49.4%)  n = 72 (47.7%) 
 
Race 
White   n = 28,989 (40.8%)  n = 73 (48.3%) p > 0.10 
Non-White  n = 42,062 (59.2%)  n = 78 (51.7%)  
 
Age 
18 - 64 years   n = 60,598 (85.3%)  n = 122 (80.8%) p > 0.10 








Table 2. Analysis of HPV-16 DNA PCR screening 
________________________________________________________________________ 
Variables  HPV-16 negative  HPV-16 positive  
                                    n = 98                                      n = 4 
________________________________________________________________________ 
Gender 
Female  n = 58 (56.9%)  n = 4 (3.9%)   
Male   n = 40 (39.2%)  n = 0 (0.0%)   
 
Race 
White   n = 44 (43.1%)  n = 0 (0.0%)   
Non-White  n = 54 (52.9%)  n = 4 (3.9%) 
 
Age 
18 - 64 years   n = 81 (79.4%)  n = 3 (2.9%)   








Table 3.  Comparison of HPV screening methods 
________________________________________________________________________ 
Sample ID PCR screening qPCR screening  True positive False positive 
________________________________________________________________________ 
2527  Positive (+)  70 copies/genome +   - 
2430  Positive (+)  111 copies/genome +   - 
2819  Positive (+)  87 copies/genome +   - 
2718  Positive (+)  96 copies/genome +   - 
________________________________________________________________________ 
Sample  PCR screening qPCR screening True negative False negative 
      > 0.001 copies/genome 
________________________________________________________________________ 
2858  Negative (-)  0.0000148  +   - 
2108  Negative (-)  0.0005   +   - 
2424  Negative (-)  0.0003   +   - 
2003  Negative (-)  0.0000016  +   - 
2208  Negative (-)  0.0003   +   - 
2739  Negative (-)  0.0007   +   - 
2051  Negative (-)  0.00001  +   - 
2809  Negative (-)  0.00004  +   - 
2782  Negative (-)  0.00008  +   - 
2821  Negative (-)  0.000036  +   - 
________________________________________________________________________ 
Change in threshold value   True negatives   True positives 
________________________________________________________________________ 
Cutoff  copies/genome >    0.1  10/10  (100%)  4/4 (100%) 
Cutoff  copies/genome >  0.01  10/10  (100%)  4/4 (100%) 






DISCUSSION & CONCLUSION 
 
General Discussion 
Socioeconomic status (SES) is a predictor of health which reflects social 
influence and individual factors, environmental exposures, stressors, and health behaviors 
in populations (Benard et al., 2008). SES includes income, education, occupation, 
location of residence, poverty level, and race. Disparities of race and gender are 
differences in patterns and exposure to risk factors. Many types of barriers to screening 
and education exist when health disparities are present.  
The health belief model fits the realm of this study because it can help explain 
why one would or would not use available preventive services. In this case, the reasoning 
of why women and minorities infrequently receive pap smears, breast exams, or oral 
cancer screening is measurable. Perceived susceptibility, perceived severity, perceived 
benefits, and perceived barriers are the four constructs that outline the health belief 
model. Self-efficacy evaluates the individual’s confidence in their ability to perform the 
action. The health belief model can assist in answering why a particular behavior occurs 
and identify ways to change the behavior. Perceived susceptibility asks the question 
whether women and minorities believe that they are at risk for developing HPV, cervical 
cancer, breast cancer, and even oral cancer. Perceived severity is whether at risk 
individuals are aware that HPV is the primary cause of cervical cancer, seen in 50% of 
breast cancer biopsies, and now seen in oral cancer patients. The perceived benefit of 
screening is potential early detection for cervical, breast, and oral cancers, thus 
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preventing cancer. Perceived barriers are what prevent at-risk individuals from getting 
screened.  
Barriers include access to health care, refusal to access care, perceived risks, 
follow up diagnosis of cancer, cultural beliefs, and most importantly lack of 
communication and education regarding preventive care options. Down’s et al., (2010) 
identified five barriers to health. These five include availability (volume and type of 
service); accessibility (location of service vs location of clientele); accommodation (ease 
of obtaining it); affordability (cost and perceived ability to pay); and acceptability 
(perceptions about practice characteristics). Minorities may be less likely to have health 
insurance, are likely to face screening barriers, and are less likely to receive treatment. 
Low income, low education, and being a minority woman are risk factors for developing 
HPV. Although access to health care may exist, it may be refused. Women in poverty 
tend to only access health care in urgent or emergency situations. In addition, minorities 
with a native language other than English may have difficulties communicating due to 
language barriers.  
Healthy People 2020 identified disparity as a particular type of health difference 
that is closely linked with social, economic, and/or environmental disadvantage (Healthy 
People 2020). The CDC (2009) referred to health disparities as differences in health 
outcomes and their determinants between segments of the population, as defined by 
social, demographic, environmental, and geographic attributes. Health disparities are 
important indicators of community health and provide information for decision making 
and potential intervention strategies used to reduce preventable morbidity and mortality 
(CDC, 2009).  
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Health disparities need to be addressed in order to increase knowledge among 
women and minorities about risks, screening, treatment, and diagnosis. These 
communities needs to be educated about HPV and its links to cervical, breast, and oral 
cancers and may be unaware of its association with different types of cancers. According 
to the CDC (2009), the Department of Health and Human Services has recognized cancer 
screening and management as one of six focus areas in which minorities face racial 
disparities in access to health and outcomes. “African American (Black) women are more 
than twice as likely to die of cervical cancer than white women and are more likely to die 
of breast cancer than are women of any other racial or ethnic group” (CDC, 2009). 
Media, including television, radio, periodicals, and the internet, are potential 
sources of information, but more specific information and awareness projects could be 
conducted to improve health literacy and health education for women and minorities. 
Media and public health campaigns, for example, might consider inclusion of several 
types of information, including some background information about HPV, modes and 
methods of transmission, prevention strategies, treatment, as well as the risk of 
developing cancer. In addition, individuals also need to be informed that HPV can be 
asymptomatic. Anhang et al., (2004) suggested that six points be emphasized when 
providing pertinent information about HPV to individuals. The six points included: (1) 
HPV is transmitted sexually; (2) HPV is very common; (3) most women with HPV will 
not develop cervical cancer; (4) HPV’s most common prognosis is infection clearing 
itself prior to treatment; (5) purpose of a Pap smear is to detect HPV-related lesions in the 
cervix suggestive of precancerous or cancerous conditions; and (6) most women who test 
positive for high risk HPV will not be diagnosed with cervical cancer or a precursor on 
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further evaluation (Anhang et al., 2004). In Healthy People 2020 (2010), the goal for 
health disparities is to achieve health equity, eliminate disparities, and improve health of 
all groups (Healthy People 2020, 2010). 
As the principal investigator of this project, HPV became an interesting and 
important topic following the presentation of Dr. Karl Kingsley’s group (class project) on 
immunizations. Although some prior knowledge and background has been circulated 
through commercial advertisement for the new HPV vaccine, Gardasil, little information 
regarding any other aspects of HPV has been available from the popular media and press. 
The presentation advised us of the links that HPV had to cervical, breast, and oral cancers 
and how minorities and women were most affected. As a woman and a minority, these 
issues represent distinct priorities.  Based upon a first-hand experience, it may be a strong 
possibility that these at-risk communities have similar barriers to information. As a public 
health graduate student, an addition goal for this paper may be to serve as an educational 
resource for women and minorities with respect to HPV, its risks, and prevention. 
Although there are many issues regarding HPV and women/minority health 
(cervical, breast, oral health), as the principal investigator, there was a major opportunity 
to take part in one specific project that targeted oral HPV. This allowed the chance to 
explore a population that is representative of minorities and females while discovering 
something new that nobody else has done in the US, an oral HPV screening of healthy 
adults in the US.  
Minorities tend to be underrepresented in research studies, possibly due to barriers 
such as fear, lack of trust, and lack of education. Overcoming these barriers could allow 
minorities to participate in more research studies allowing researchers to establish 
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community specific education and awareness. Eliminating barriers could improve 
screening and lower morbidity and mortality rates in minorities and women. Screening is 
a preventive measure that can lower incidence rates in minorities and women and extend 
their duration of life. Screening, education, and eliminating barriers are essential for 
lowering risks in women and minority patients. 
Future studies 
Future studies conducted between the School of Community Health Sciences and 
Dental Medicine should continue the oral HPV screening while testing for HPV 18, 
another high risk strain, in addition to HPV 16. Also, a learning module should be created 
for females and minorities to educate about HPV and its relation to cervical, breast, and 
oral health. In addition, future students should see how many UNLV-SDM patients 
(female) have pap smears and dental screenings (male/female) regularly.  
Conclusions and Significance 
Analysis of the UNLV-SDM patient population revealed a higher percentage of 
females and minorities than in the local community, Clark County.  Analysis of the 
demographic information from the saliva samples revealed that these samples were 
representative of the UNLV-SDM patient pool.  Four (4) samples tested positive for 
HPV16 (all from women and minority participants) from more than one hundred samples 
screened (n=102). This study is significant because it is the first saliva-based oral HPV 
screening on healthy adults to be completed in the U.S. and only the third study of its 
kind overall.   
In conclusion, although this study provides valuable information, it also had 
several limitations.  These include the limited screening for only one HPV type, HPV16.  
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HPV16 is the most common HPV strain found in the oral cavity and was therefore 
selected for this pilot study, although future studies could evaluate other high-risk HPV 
strains, such as HPV18.  In addition, detailed demographic information were not obtained 
in this study, although future studies could evaluate other demographic variables, 
including tobacco and alcohol use, education, income, and even knowledge of HPV.  
Even though the prevalence of HPV16 in this study was relatively low (3.9%), it is 
comparable to other studies of oral HPV (range 0 -21%).  Future studies might 
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